Results

1–6 of 6 results for non-proliferative diabetic retinopathy

Association Between DRSS Changes and Visual/ Anatomic Outcomes in Patients With Moderately Severe to Severe NPDR: Post Hoc Analysis of PANORAMA
Diana V Do, MD, FASRS
Annual Meeting Talks
2022
Impact of Intravitreal Anti-VEGF Therapy for Severe Non-Proliferative Diabetic Retinopathy (NPDR): Analyses Through a Monte-Carlo Simulation Model
Andrew A. Moshfeghi, MD, MBA, FASRS
On Demand Cases, Courses, and Papers
2021
Amine Oxidase Copper-Containing 3 Inhibitor (BI 1467335) in Non-Proliferative Diabetic Retinopathy: Double-Masked, Randomized, Phase IIa Study (ROBIN)
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Annual Meeting Talks
2021
Long-term Clinical Impact of Intravitreal anti-VEGF Therapy for Severe Non-proliferative Diabetic Retinopathy (NPDR): Analyses Through a Discrete Event Simulation Model
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2021
Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): The Phase 3 PANORAMA Study
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2018
Treatment of Moderately Severe to Severe Non-proliferative Diabetic Retinopathy with Intravitreal Aflibercept Injection
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2019